Haisco(SZ:002653) Sou Hu Cai Jing·2025-08-01 12:22Core Viewpoint - The financial performance of Haishike (002653) shows a mixed picture with revenue growth but a significant decline in net profit, indicating potential challenges ahead for the company [1]. Financial Performance - As of the first quarter of 2025, Haishike reported total revenue of 892 million yuan, representing a year-on-year increase of 18.60% [1]. - The net profit attributable to shareholders was 46.61 million yuan, a decrease of 49.31% year-on-year [1]. - The non-recurring net profit was 50.34 million yuan, showing a year-on-year growth of 69.25% [1]. - The company's liquidity ratios are strong, with a current ratio of 1.907 and a quick ratio of 1.695, while the debt-to-asset ratio stands at 40.59% [1]. Market Activity - On August 1, 2025, Haishike's stock closed at 53.87 yuan, down 3.44%, with a turnover rate of 0.99% and a trading volume of 53,000 lots, amounting to a transaction value of 289 million yuan [1]. - The net inflow of main funds was 13.16 million yuan, accounting for 4.55% of the transaction value, with large orders showing a net inflow of 24.19 million yuan [1]. Company Background - Haishike Pharmaceutical Group Co., Ltd. was established in 2005 and is primarily engaged in the pharmaceutical manufacturing industry [2]. - The company has a registered capital of 1.12 billion yuan and is located in Shannan City [1][2]. - Haishike has made investments in 20 enterprises and participated in 36 bidding projects, holding 493 trademark registrations and 69 patents [2].